Glucantime - quality control

[Kleber Giovanni]

Caso 

----------
> De: Susanne Rath <raths at iqm.unicamp.br>
> Para: Multiple recipients of list <leish-l at bdt.org.br>
> Assunto: Glucantime - quality control
> Data: Terça-feira, 26 de Janeiro de 1999 11:11
> 
> Dear Sirs,
> My name is Susanne Rath and right now I register me in the Leishmaniasis
> Network List. I was happy to found this site and I am looking forward to
> the possibility to change scientific informations.
> I am working with the characterization of the N-methylglucamine
> antimoniate, particullary with the quantification of antimony (V) in
> drugs employed in the terapy of leishmaniasis in Brazil. I started with
> this research after various discussions that I had  with Dr. Philipp
> Marsden from the University of Brasília.   According to Dr. Philip,
> therapeutic efficacy and side effect of the drug depends of the batch
> lot employed. In our studies we confirmed that the content of the
> pentavalent antimony changes from batch to batch and contamination of
> antimony (III) was detected in all samples analyzed.
> In this way, I would appreciate if I could have more information about
> variation in efficacy and side effects observed in patient treated with
> Glucantime that will be confirm our results.
> Is there another group working with the standardization of Glucantime or
> Pentostam?
> Many thanks,
> Best regards,
> 
> Dr. Susanne Rath
> Departamento de Química Analítica
> Instituto de Química
> Universidade Estadual de Campinas
> Caixa Postal 6154
> 13.083-970 Campinas, SP, Brazil
> Tel.: 55-19-788 3084
> FAX: 55-19-7883023
> E-mail: raths at iqm.unicamp.br
>